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Abstract
Background: Irritable bowel syndrome (IBS) is associated with other disorders (comorbidity), reduced quality of life
and increased use of health resources. We aimed to explore the impact of comorbidity on cost of health care in
patients with IBS in general practice.
Methods: In this cohort study 208 consecutive patients with IBS (Rome II) were recruited. Sociodemographic data,
IBS symptoms, and comorbidity (somatic symptoms, organic diseases and psychiatric disorders) were assessed at
baseline. Based on a follow up interview after 6-9 months and use of medical records, IBS and non-IBS related
health resource use were measured as consultations, hospitalisations, use of medications and alternative health
care products and sick leave days. Costs were calculated by national tariffs and reported in Norwegian Kroner
(NOK, 1 EURO equals 8 NOK). Multivariate analyses were performed to identify predictors of costs.
Results: A total of 164 patients (mean age 52 years, 69% female, median duration of IBS 17 years) were available at
follow up, 143 patients (88%) had consulted their GP of whom 31 (19%) had consulted for IBS. Mean number of
sick- leave days for IBS and comorbidity were 1.7 and 16.3 respectively (p < 0.01), costs related to IBS and
comorbidity were 954 NOK and 14854 NOK respectively (p < 0.001). Age, organic diseases and somatic symptoms,
but not IBS severity, were significant predictors for total costs.
Conclusion: Costs for health resource use among patients with IBS in general practice were largely explained by
comorbidity, which generated ten times the costs for IBS.
Background
Irritable bowel syndrome (IBS) is a functional gastroin-
testinal disorder (FGID) affecting 8%-20% of the adult
population in the western countries [1-3]. IBS is consid-
ered a significant burden for patients and society due to
reduced quality of life and increased use of health
resources [2,4,5]. Patients with IBS consume over 50%
more health-care resources than matched controls with-
out IBS [6]. A systematic review of studies addressing
the direct and indirect costs of IBS in the US and UK
included 18 of 24 identified publications between 1991
and 2003 [7]. Total direct cost estimates per person per
year ranged from US Dollar (USD) 348 to USD 8750
and indirect costs ranged from USD 355 to USD 3344.
Costs were influenced by a range of factors including
age, consultation behaviour, comorbidity and severity of
symptoms. The review recommended further studies to
take these influential factors into account. Nevertheless,
a common inference and argument for development of
drugs towards symptoms of IBS is that the increased
health care use and reduced quality of life is due to
symptoms of IBS [8].
Consideration of comorbidity as an explanatory factor
for use of health resources is warranted since patients
with IBS frequently report other somatic and psychiatric
disorders [9,10]. Such comorbidity might have a signifi-
cant impact on health resource use and costs for
patients with IBS. Most research on IBS has been per-
formed on referred patients with IBS with questionable
applicability in a general practice setting. Since most
patients with IBS are managed in general practice, we
aimed to measure health resource use and its costs in
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factors generating these costs.
Methods
Study design and material
This prospective cohort study was designed to identify
and follow up a representative sample of patients with
IBS (according to Rome II criteria) in Norwegian gen-
eral practice. Of 3369 consecutive patients consulting
their GP, 3092 (92%) answered a short questionnaire
regarding abdominal complaints, prior to the consulta-
tion. Of 830 patients with abdominal complaints, for
which they had consulted or wanted to consult their
GP, 733 (89%) were assessed with the Rome II criteria
for functional bowel disorders [11]. Of the 733 patients
278 patients had IBS according to the Rome II criteria.
These 278 patients were invited to participate if the GP,
based on all available information about the patient,
agreed on the IBS diagnosis. A total number of 208
patients with IBS were included. Details about study
design are given elsewhere [10]. The patients were
invited by informed consent to further characterisation,
by completing questionnaires at the first visit. After 6-9
months, included patients were invited to a follow up
interview with repeated assessment of symptoms and
detailed assessment of health resource use. No specific
attention towards the abdominal complaints was to be
given by the GP in the follow up period.
The study was performed during 2001in the county of
Oppland in Norway, with 26 participating GPs working
in nine health centres. In Norway, patients must seek
health care through their locally assigned GP. Members
of the practice staff (study nurses) performed the practi-
cal work related to the study. They were released from
other duties, and trained to ensure satisfactory protocol
adherence.
All patients were characterised at baseline for sociode-
mographic data and somatic and psychiatric comorbidity
by self-completed questionnaires. Sociodemographic
data included age, gender, smoking status, alcohol use,
education (> 10 years), working status (employed, dis-
ability benefit, retired, students). IBS symptoms were
assessed for severity and duration. Severity was mea-
sured as mild (with no interference of daily activities),
moderate (with some interference, but no disruption of
daily activities) and severe (with disruption of daily
activities) with scores 1-3, and frequency as average
number of days per week with abdominal pain/discom-
fort (0-1/2-3/4-5/> 5) with scores 1-4. An IBS symptom
score was calculated by multiplying severity and fre-
quency (range 1-12). Somatic diseases were measured by
12 questions about different organic diseases present
within the 3 last months (yes/no) and presented as a
sum-score (range 0-12). Somatic symptoms were
measured by 17 questions about somatic symptoms
from the Subjective Health Complaints (SHC) inventory
[12]. The SHC inventory consists of a list of 29 common
health complaints experienced the last 30 days, with the
intensity of each complaint graded on a four point scale
(not at all/little/some/severe). An SHC total score is cre-
ated by adding the scores of each item. 12 questions
about gastroenterological and psychiatric symptoms
were excluded to avoid duplicate assessment, giving a
SHC-17 score from 0 to 51. Psychiatric comorbidity was
measured by Symptom Check List 10 (SCL-10, score
range 1 - 4.0), which measures psychological distress,
with a cut off point of > 1.85 as a valid predictor of
mood disorder. Health anxiety was measured by Whitley
index (score range 14-60) and neuroticism by EPQ-10
(score range 0-10) [13-15].
Measurement of health resource use and
associated costs
Health resource use and associated costs were measured
for investigations, consultations, hospitalisations, medica-
tions, and alternative health care products and number of
sick leave days was noted. Assessment was primarily
done by structured questions in a Case Report Form
(CRF) completed by study nurses at the follow up inter-
view. All questions in the CRF separated use of health
resources related to symptoms of IBS (IBS-related) from
use of health resources related to other symptoms and
diseases (comorbidity-related). Nurses were instructed to
examine the electronic medical records (EMR) to identify
relevant information. If information was not available in
the EMR, data were assessed by patients recall. Since fol-
low up time varied between six and nine months, only
the last six months of the follow up period was used to
measure use of health resources. The cost analysis was
restricted to direct medical costs for health resource use
and did not include sick-leave days, which we considered
an indirect cost.
Investigations were assessed only for IBS and included
blood samples, stool tests, endoscopic procedures and
medical imaging by x-ray, CT, MRI and ultrasound.
Costs for consultations and investigations were calcu-
lated using National Tariffs for the Public Health Service
for year 2001, in Norwegian kroner (NOK, €1e q u a l s
NOK 8). Consultations were measured as the number of
visits to GPs, specialists, chiropractors, physiotherapists,
psychotherapists and alternative health care providers.
Hospitalisations were measured as numbers of hospital
stays for each patient. Costs for hospitalisations were
calculated using Diagnosis Related Groups (DRG) and
national tariffs. Medications were measured as total use
of drugs by physicians’ prescription and drugs purchased
over the counter. Medication costs were calculated by
The Norwegian Pharmaceutical Product Compendium
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calculated using the lowest dose 3 times per week.
Alternative health care products and their costs were
measured and estimated by patients recall. Sick-leave
days were measured directly by retrieving data from the
EMR.
Data analysis and statistics
Data were analysed by descriptive statistical methods in
SPSS v. 15. Use of health resources and its costs were ana-
lysed by univariate, bivariate and multivariate analyses.
Non-parametric tests (eg. Wilcoxon, Spearman’s rho and
Mann Whitney U test) were performed in the cost analyses
due to skewed distribution of costs as dependent variables.
Variables with p < 0.2 in the bivariate analyses were
entered in multivariate lineary regression analyses. Age and
gender were kept as sociodemographicvariables in the mul-
tivariate analysis, regardless of statistical significance in
bivariate analysis, and the dependent variables (costs) were
log 10 transformed.
Ethics
The study was performed according to the Declaration
of Helsinki and approved by the Regional Committee
for Medical Research Ethics and the Data Inspectorate,
Oslo, Norway.
Results
Characteristics of patients
Table 1 gives the characteristics of the 164 patients who
were available at the follow up after 6-9 months and
included in the analyses. The 44 patients lost to follow-up
(36-unwilling or no contact, 6- organic diseases diagnosed
and 2- missing data in CRF) did not differ significantly
from patients included in the analyses for any of the base-
line characteristics (data not shown).
Use of health resources and associated costs
In the 6 month follow up period, 143 patients (88%)
consulted their GP of whom 31 (19%) consulted for
IBS-complaints. The mean number of visits was 3.6 (SD
2.9). As for investigations for IBS-complaints in the
study period, blood tests were performed in 24 patients
(15%), endoscopy in 8 patients (5%) and barium enema
in14 patients (9%). Medications were used by 146
patients (89%) of whom 14 (9%) used medications for
symptoms of IBS. Sick-leave days related to IBS were
significantly lower than related to comorbidity (mean
1.7 days (SD 16) versus 16.3 days (SD 43), p < 0.001).
Table 2 gives the costs of health care in the 6 month
follow up period. Median total costs related to symp-
toms of IBS and comorbidity were NOK O (0-59728)
and NOK 3190 (range 0-193355) respectively. The med-
ian costs for investigations related to IBS were NOK O
(range 0-2170).
Factors associated with and predicting costs for
health resource use
T a b l e3a n d4g i v et h ea s s o c i a tions (shown as bivariate
and multivariate analyses) between the background vari-
ables and costs. Age, organic diseases and somatic
symptoms were significant independent predictors for
total costs; mood disorder was a significant predictor for
the use of alternative products. IBS symptom score
(severity and frequency) was not associated with any of
the cost variables included IBS-related costs.
Discussion
Main findings
This study found that costs for health care generated by
patients with IBS were mainly driven by comorbidity.
Our finding that comorbid disorders generated approxi-
mately ten times the costs for IBS was consistent for
consultations, hospitalisations, medications and use of
alternative health care products. A similar pattern was
found for sick leave days although we did not compute
costs for this dimension of health resource use. We are
not aware of other studies demonstrating a similar dif-
ference in IBS-related and comorbidity-related use of
health resources. Another noteworthy finding was the
limited use of health resources related to symptoms of
IBS. Less than one third of patients reported consulta-
tions, investigations or the use of medications for IBS
during the six-month follow-up period. In contrast,
patients on average consulted their GP nearly four times
Table 1 Characteristics of 164 patients with IBS included
in the analyses
Variables
Age (years), mean (SD) 52 (15.1)
Female gender 69%
Gastro-esophageal reflux (Rome II definition) 43%
Dyspepsia (Rome II definition) 9%
Duration IBS complaints (> 1 year) 85%
Duration IBS in years, mean (SD) 17 (15)
IBS-severity (mild/moderate/severe) 36%/52%/12%
Education > 10 years 63%
Mood disorder (SCL 10 > 1.85) 37%
Number of organic diseases, mean (SD) 2.0 (1.8)
Smokers 35%
Alcohol use (> 2 occasions/week) 18%
SHC-17, mean (SD) 13.2 (8.2)
EPQ, mean (SD) 4.0 (2.9)
Whitley, mean (SD) 25.9 (8.2
SCL-10, mean (SD) 1.8 (0.6)
Results are reported as percentages if not otherwise specified.
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time. As we have published earlier, our sample of
patients were characterized by high levels of somatic
and psychiatric comorbidity [10]. Importantly, the total
direct costs for health care generated by our sample lie
within the range of costs reported in the systematic
review of costs for IBS in the US and UK [7]. Taken
together the findings suggest that from a health eco-
nomic perspective symptoms of IBS constitute a minor
problem but patients with IBS constitute a major pro-
blem. Patients with IBS referred to specialists exhibit
more severe IBS symptoms than patients handled in
general practice [16]. Since these patients also exhibit
higher levels of comorbidity than patients in general
practice it would be useful to study the impact of
comorbidity on health resource use in secondary health
care [9]. This was partly investigated in a study of
referred patients with severe IBS in the UK [17]. Inter-
estingly, abdominal and psychological symptoms were
independently associated with impaired health-related
quality but the authors could not find predictors for the
observed excess health care costs and loss of productiv-
ity. Given the findings in our study one likely predictor
would be the somatic comorbidity, which was not
included as an explanatory factor in the UK study.
Knowledge about predictors of health care costs in
patients with IBS can help target interventions to reduce
such costs. Our multivariate analyses revealed age,
somatic comorbidity (ie. number of organic diseases and
somatic symptoms) and psychiatric comorbidity as main
predictors of different domains of health care costs. The
individual predictive values of these factors are limited
by the significant correlation between somatic and psy-
chological comorbidity in this sample of patients (r
2 =
46%) [10]. Accordingly, bivariate analyses revealed sev-
eral somatic and psychiatric comorbidity-variables to be
associated with most domains of health care costs. In
contrast to what has been reported by Longstreth et al,
severity of IBS symptoms did not predict costs for IBS-
related health care or total costs for health care in our
study [18]. This discrepancy is most likely explained by
our use of multivariate analyses to control for the
Table 2 IBS and comorbidity-related costs of health care measured in Norwegian Kroner (NOK) in the six-month
follow-up period
Type of health resource IBS-related costs Comorbidity-related costs p-values*
Consultations 169 (610)
0 (0-5520)
1315 (1915)
539 (0-12688)
P < 0.001
Hospitalisations 710 (6413)
0 (0-58260)
10302 (27330)
0 (0-174780)
P < 0.001
Medications 47 (261)
0 (0-2785)
2999 (6796)
1544 (0-74634)
P < 0.001
Alternative products 26(127)
0 (0-1110)
238(544)
5 (0-4000)
P < 0.001
Total 1049(6574)
0 (0-60468)
14856(30570)
3190 (0-193355)
P < 0.001
*Wilcoxon test due to skewed data.
Results are given both as mean (SD) and median with range (italic). €1 equals NOK 8.
Table 3 Associations between background variables and costs of health care in the six-month follow up period
Variables Costs for
consultations
Costs for
hospitalisations
Costs for
medications
Costs for alternative
products
Total
costs
Total IBS related
costs
Age 0.841 0.579 0.001 0.182 0.003 0.498
Gender (female) 0.692 0.612 0.610 0.125 0.965 0.192
Education > 10 yrs 0.406 0.465 0.008 0.126 0.251 0.929
Smoker 0.631 0.725 0.607 0.301 0.567 0.531
Alcohol use 0.687 0.046 0.854 0.834 0.552 0.813
Reflux/Dyspepsia 0.261 0.543 0.309 0.388 0.385 0.427
IBS-symptom score 0.148 0.767 0.001 0.838 0.075 0.059
Somatic symptom score
(SHC-17)
0.001 0.713 0.001 0.002 0.001 0.524
Organic disease score 0.003 0.014 0.001 0.434 0.001 0.914
Neurotissism 0.151 0.796 0.076 0.006 0.224 0.288
Health anxiety 0.008 0.873 0.024 0.105 0.132 0.892
Mood disorder (SCL 10) 0.292 0.975 0.050 0.001 0.140 0.338
The results are given as p-values with significant values in bold. For all background variables higher values were associated with increased costs.
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Other possible explanations include our crude measure-
ment of IBS severity, the limited sample size and our
sampling of patients with long standing symptoms who
did not necessarily primarily consult for symptoms of
IBS at the time they were included in this study. The
latter possible explanation is reflected in the observed
low number of investigations performed for IBS and the
low median costs for medications for IBS. If we had
included only patients with recently onset severe symp-
toms of IBS the costs for IBS-related health care would
likely have been more impressive. The finding that
increasing age independently predicted health care costs
could be explained by sociodemographic factors or
comorbidities (ie. more severe diseases and/or longer
stays in hospitals) not captured by our analyses.
The considerable impact of comorbidites on health
resource use observed in our study is unlikely to be
unique to patients with IBS. A fairly similar pattern
would probably emerge if we had included patients with
a primary diagnosis of for example chronic low back
pain, fibromyalgia or chronic fatigue syndrome instead
of IBS as the qualifying diagnosis. Accordingly a sys-
tematic review of patients with chronic low back pain
found an association between comorbid mood disorders
and health care costs [19]. More recently a study of 16
567 patients with chronic low back pain reported that
physical and mental health comorbidities were asso-
ciated with healthcare utilization and costs [20]. The
findings highlight the need to maintain a wide focus not
restricted to specific diagnoses both in clinical research
and practice for patients with a variety of somatic and
psychiatric illness.
Strengths and limitations
Among the strengths of this study are the cohort study
design, the high follow up rate and the meticulous
retrieval of data from the EMR concerning consulta-
tions, hospitalisations, medications and sick-leave days.
Another strength is that the IBS diagnosis was based on
the internationally recognised Rome II-criteria designed
for research purposes [11]. The Rome II criteria have
now been superseded by the Rome III criteria but only
minor changes have been made regarding the diagnosis
of IBS. A weakness of our study and possible source of
information error is that the use of medications over the
counter, alternative health care and presence of organic
diseases were assessed by patients recall. Another possi-
ble source of information error is that study nurses who
were aware of the objectives in the study and responsi-
ble for collecting data at follow up could have influ-
enced categorization of health resources as related to
IBS or related to comorbidity. Another potential weak-
ness is that we can not determine to what extent
patients with IBS in our study used more health
resources than patients in general practice without IBS.
However, this has been firmly established by others [7].
Conclusion
It seems reasonable to conclude that effective treatment
targeting IBS symptoms alone will have limited impact
on the use of health resources generated by these
patients in a general practice setting. Our findings call
for research to establish the impact of comorbidity on
use of health resources and quality of life in different
clinical settings. We suggest that future research to
improve treatment for patients with IBS should take
into consideration comorbidity as a main driver for
health resource use and reduced quality of life [21]. The
comorbidity of IBS has implications for choice of inter-
ventions (e.g mind body intervention) and outcomes in
design of treatment trials [22,23]. Regarding choice of
outcomes we suggest that both somatic and psychiatric
comorbidities are included as patient-important out-
comes together with symptoms of IBS, quality of life
and use of health resources in future trials. For clini-
cians who encounter patients with IBS in clinical prac-
tice our study pinpoints the importance of a holistic
Table 4 Multivariate analyses of variables associated with costs of health care (p < 0.20) in bivariate analysis
Costs Age Gender Organic diseases Somatic symptoms Mood disorder IBS symptom score Alcohol use
Costs for consultations ns ns b = 0.133
p = 0.002
ns ns ns ns
Costs for hospitalisations ns ns b = 0.184
p = 0.031
ns ns ns b = 0.915
p = 0.025
Costs for medications b = 0.032
p = 0.001
ns ns b = 0.031
p = 0.002
ns ns ns
Costs for alternative products b = 0.013
p = 0.052
ns ns ns b = 0.484
p = 0.004
ns ns
Total costs b = 0.013
p = 0.008
ns b = 0.090
p = 0.047
b = 0.021
p = 0.034
ns ns ns
Total costs for
IBS
ns ns ns ns ns ns ns
Results are given as b and p-values if statistically significant associations were found (p < 0.05) or as non-significant (ns).
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[24,25].
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